Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors

AIDS

Volumn 14, Issue 3, 2000, Pages 237-242

  Huisman, Maarten T ^a   Smit, Johan W ^a   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Blood brain barrier; HIV protease inhibitor; HIV transmission; P glycoprotein; Placenta

Indexed keywords

GLYCOPROTEIN P; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD BRAIN BARRIER; DRUG BIOAVAILABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KNOCKOUT MOUSE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PLACENTAL TRANSFER; PRIORITY JOURNAL; REVIEW; TISSUE DISTRIBUTION; VIRUS TRANSMISSION;

ANIMALS; ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN;

EID: 0034052258     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200002180-00005     Document Type: Review

References (62)

1. 1. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291-1295.
2. 2. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
3. 3. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976, 455:152-162.
4. 4. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993, 62:385-427.
5. 5. Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 1992, 8:67-113.
6. 6. Kim AE, Dintaman JM, Waddell DS, Silverman JA. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 1998, 286:1439-1445.
7. 7. Lee CG, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998, 37:3594-3601.
8. 8. Alsenz J, Steffen H, Alex R. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm Res 1998, 15:423-428.
9. 9. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998, 101:289-294.
10. 10. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981, 41:1967-1972.
11. 11. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990, 42:155-199.
12. 12. Sikic BI. Pharmacologic approaches to reversing multidrug resistance. Semin Hematol 1997, 34:40-47.
13. 13. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 1991, 51:4226-4233.
14. 14. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridone-carboxamide derivative. Cancer Res 1993, 53:4595-4602.
15. 15. Dantzig AH, Shepard RL, Cao J, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996, 56:4171-4179.
16. 16. Smith AJ, Mayer U, Schinkel AH, Borst P. Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. J Natl Cancer Inst 1998, 90:1161-1166.
17. 17. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77:491-502.
18. 18. Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997, 94:4028-4033.
19. 19. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989, 86:695-698.
20. 20. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and cross-reactivity of one antibody with a muscle protein. J Histochem Cytochem 1989, 37:159-164.
21. 21. Saito T, Zhang ZJ, Shibamori Y, et al. P-glycoprotein expression in capillary endothelial cells of the 7th and 8th nerves of guinea pig in relation to blood-nerve barrier sites. Neurosci Lett 1997, 232:41-44.
22. 22. van Asperen J, Mayer U, van Tellingen O, Beijnen JH. The functional role of P-glycoprotein in the blood-brain barrier. J Pharm Sci 1997, 86:881-884.
23. 23. Enting RH, Hoetelmans RM, Lange JM, Burger DM, Beijnen JH, Portegies P. Antiretroviral drugs and the central nervous system. AIDS 1998, 12:1941-1955.
24. 24. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995, 96:1698-1705.
25. 25. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996, 97:2517-2524.
26. 26. Mayer U, Wagenaar E, Beijnen JH, et al. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol 1996, 119:1038-1044.
27. 27. Jonker JW, Wagenaar E, van Deemter L, et al. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug. Br J Pharmacol 1999, 127:43-50.
28. 28. Foudraine NA, Hoetelmans RMW, Lange JM, et al. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998, 351:1547-1551.
29. 29. Hoetelmans RMW, Reijers MH, Weverling GJ, et al. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998, 12:F111-F115.
30. 30. Hoetelmans RMW. Sanctuary sites in HIV-1 Infection. Antiviral Therapy 1998, 3(suppl. 4):13-17.
31. 31. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987, 84:7735-7738.
32. 32. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990, 38:1277-1287.
33. 33. van Asperen J, van Tellingen O, Beijnen JH. The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol Res 1998, 37:429-435.
34. 34. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997, 94:2031-2035.
35. 35. Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997, 11:F29-33.
36. 36. Perry CM, Noble S. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection. Drugs 1998, 55:461-486.
37. 37. Hoetelmans RMW, Meenhorst PL, Mulder JW, Burger DM, Koks CHW, Beijnen JH. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci 1997, 19:159-175.
38. 38. Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 1997, 25:256-266.
39. 39. Smit JW, Schinkel AH, Weert B, Meijer DKF. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted. Br J Pharmacol 1998, 124:416-424.
40. 40. van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, van Tellingen O. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J Natl Cancer Inst 1996, 88:994-999.
41. 41. van Asperen J, van Tellingen O, Tijssen F, Schinkel AH, Beijnen JH. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br J Cancer 1999, 79:108-113.
42. 42. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991, 66:85-94.
43. 43. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994, 83:2451-2458.
44. 44. Drach D, Zhao S, Drach J, et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992, 80:2729-2734.
45. 45. Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol 1998, 12:457-463.
46. 46. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 1999, 104:1441-1447.
47. 47. Sugawara I, Kataoka I, Morishita Y, et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 1988, 48:1926-1929.
48. 48. van Kalken C, Giaccone G, van der Valk P, et al. Multidrug resistance gene (P-glycoprotein) expression in the human fetus. Am J Pathol 1992, 141:1063-1072.
49. 49. MacFarland A, Abramovich DR, Ewen SW, Pearson CK. Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta. Histochem J 1994, 26:417-423.
50. 50. Nakamura Y, Ikeda S, Furukawa T, et al. Function of P-glycoprotein expressed in placenta and mole. Biochem Biophys Res Commun 1997, 235:849-853.
51. 51. Newell ML. Mechanisms and timing of mother-to-child transmission of HIV-1. AIDS 1998, 12:831-837.
52. 52. Casey BM, Bawdon RE. Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. Am J Obstet Gynecol 1998, 179:758-761.
53. 53. van Asperen J, van Tellingen O, Sparreboom A, et al. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer 1997, 76:1181-1183.
54. 54. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 1997, 100:2430-2436.
55. 55. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998, 161:5733-5744.
56. 56. van Asperen J, van Tellingen O, van der Valk MA, Rozenhart M, Beijnen JH. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res 1998, 4:2293-2297.
57. 57. Hendrikse NH, Schinkel AH, de Vries EGE, et al. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 1998, 124:1413-1418.
58. 58. Meerum Terwogt JM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Schellens JHM. Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet 1998, 352:285.
59. 59. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Med 1999, 5:512-517.
60. 60. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998, 35:275-291.
61. 61. Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998, 63:453-464.
62. 62. Koudriakova T, Iatsimirskaia E, Utkin I, et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 1998, 26:552-561.